Table 2
Developed synthetic ligands for corresponding SIGLECs
| SIGLECs | Natural ligands | High affinity synthetic ligands | Refs |
|---|---|---|---|
| SIGLEC1 | Neu5Acα2,3LacNAc Modest |  TCCNeu5Ac (1) (R = α2,3-LacNAc, IC50 = 0.38 μM) | 87 |
| hCD22* | Neu5Acα2,6LacNAc Strong |  BPCNeu5Ac (2) (R = α2,6-LacNAc, IC50 = 0.20 μM) | 99 |
 MPBNeu5AcF (3) (R = α2,6-Lac, IC50 = 0.20 μM) | 100 | ||
| mCD22** | Neu5Gcα2,6LacNAc Strong |  BPANeu5Gc (4) (R = α2,6-LacNAc, IC50 = 0.80 μM) | 99 |
| hCD33*** | Neu5Acα2,6LacNAc Weak |  (5) (R = α2,6-Lac, IC50 = 11.00 μM) | 100 |
| SIGLEC7 | Neu5Acα2,8Neu5Acα2,3LacNAc Strong |  FTMCNeu5Ac (6) (R = α2,6-Lac, unknown affinity) | 89 |
| SIGLEC9 | Neu5Acα2,3Galβ1,4(Fucα1,3)-(6-O-SO3)GlcNAc Strong [Ref. 101] |  (7) (R = α2,6-Lac, unknown affinity) | 102 |
| SIGLEC15 | Neu5Acα2,6GalNAcαThr/Ser (To be further evaluated) [Ref. 103] |  (8) (R = α2,6-LacNAc, unknown affinity) | 90 |
LacNAc, Galβ1,4GlcNAc; Lac, Galβ1,4Glc; IC50, half maximal inhibitory concentration. *hCD22, human SIGLEC2/CD22. **mCD22, mouse SIGLEC2/CD22. ***hCD33, human SIGLEC3/CD33.